3 Reasons SUPN is Risky and 1 Stock to Buy Instead
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q4 CY2025: Strong Sales
Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four...
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central...
Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead
ROCKVILLE, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central...
1 Cash-Heavy Stock on Our Buy List and 2 We Brush Off
1 Healthcare Stock to Consider Right Now and 2 We Brush Off